Dr. Cremolini on Identifying Molecular Markers in mCRC

Chiara Cremolini, MD
Published: Wednesday, Feb 25, 2015



Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

Cremolini does not believe any clinical trials based on molecular markers can currently be planned, because researchers have not encountered any with promising results. However, she says it is crucial for there to be a collection of biological samples of patients enrolled in the TRIBE-2 trial, a phase III study that will compare first-line FOLFOXIRI plus bevacizumab followed by FOLFOXIRI plus bevacizumab at progression, to FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at disease progression.

A final analysis of this study may allow researchers to answer questions regarding molecular markers in mCRC.



Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

Cremolini does not believe any clinical trials based on molecular markers can currently be planned, because researchers have not encountered any with promising results. However, she says it is crucial for there to be a collection of biological samples of patients enrolled in the TRIBE-2 trial, a phase III study that will compare first-line FOLFOXIRI plus bevacizumab followed by FOLFOXIRI plus bevacizumab at progression, to FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at disease progression.

A final analysis of this study may allow researchers to answer questions regarding molecular markers in mCRC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x